CA2145545A1 - "sensitizing hiv-1 inhibitors" sensitize hiv infected individuals to "non-nucleoside hiv treatment drugs" - Google Patents

"sensitizing hiv-1 inhibitors" sensitize hiv infected individuals to "non-nucleoside hiv treatment drugs"

Info

Publication number
CA2145545A1
CA2145545A1 CA002145545A CA2145545A CA2145545A1 CA 2145545 A1 CA2145545 A1 CA 2145545A1 CA 002145545 A CA002145545 A CA 002145545A CA 2145545 A CA2145545 A CA 2145545A CA 2145545 A1 CA2145545 A1 CA 2145545A1
Authority
CA
Canada
Prior art keywords
hiv
treatment drug
methyl
amino
nucleoside
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002145545A
Other languages
English (en)
French (fr)
Inventor
William Gary Tarpley
Thomas Jerome Dueweke
Donald Herman Batts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia and Upjohn Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2145545A1 publication Critical patent/CA2145545A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002145545A 1992-10-28 1993-09-10 "sensitizing hiv-1 inhibitors" sensitize hiv infected individuals to "non-nucleoside hiv treatment drugs" Abandoned CA2145545A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US96763992A 1992-10-28 1992-10-28
US967,639 1992-10-28
US1711993A 1993-02-12 1993-02-12
US017,119 1993-02-12

Publications (1)

Publication Number Publication Date
CA2145545A1 true CA2145545A1 (en) 1994-05-11

Family

ID=26689480

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002145545A Abandoned CA2145545A1 (en) 1992-10-28 1993-09-10 "sensitizing hiv-1 inhibitors" sensitize hiv infected individuals to "non-nucleoside hiv treatment drugs"

Country Status (12)

Country Link
EP (1) EP0666744A1 (fi)
JP (1) JPH08502745A (fi)
KR (1) KR950703958A (fi)
AU (1) AU4848293A (fi)
CA (1) CA2145545A1 (fi)
CZ (1) CZ69695A3 (fi)
FI (1) FI952018A (fi)
HU (1) HUT72050A (fi)
MX (1) MX9306031A (fi)
NO (1) NO951608L (fi)
PL (1) PL308551A1 (fi)
WO (1) WO1994009781A1 (fi)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW406075B (en) * 1994-12-13 2000-09-21 Upjohn Co Alkyl substituted piperidinyl and piperazinyl anti-AIDS compounds
US6803362B2 (en) 2001-03-09 2004-10-12 Ortho-Mcneil Pharmaceutical Inc. Heterocyclic compounds
CA2497827A1 (en) 2002-09-06 2004-03-18 Janssen Pharmaceutica, N.V. (1h-benzoimidazol-2-yl)-(piperazinyl)-methanone derivatives and related compounds as histamine h4-receptor antagonists for the treatment of inflammatory and allergic disorders
TW201201813A (en) 2010-03-31 2012-01-16 Arqule Inc Substituted benzo-pyrido-triazolo-diazepine compounds
US8569331B2 (en) 2010-11-01 2013-10-29 Arqule, Inc. Substituted benzo[f]lmidazo[1,2-d]pyrido[2,3-b][1,4]diazepine compounds

Also Published As

Publication number Publication date
NO951608D0 (no) 1995-04-27
WO1994009781A1 (en) 1994-05-11
AU4848293A (en) 1994-05-24
PL308551A1 (en) 1995-08-21
KR950703958A (ko) 1995-11-17
FI952018A0 (fi) 1995-04-27
FI952018A (fi) 1995-04-27
MX9306031A (es) 1994-04-29
EP0666744A1 (en) 1995-08-16
CZ69695A3 (en) 1995-12-13
JPH08502745A (ja) 1996-03-26
NO951608L (no) 1995-06-28
HU9501218D0 (en) 1995-06-28
HUT72050A (en) 1996-03-28

Similar Documents

Publication Publication Date Title
RU2478387C2 (ru) ИМИДАЗОХИНОЛИНЫ В КАЧЕСТВЕ ДВОЙНЫХ ИНГИБИТОРОВ ЛИПИДКИНАЗЫ И mTOR
KR100658489B1 (ko) Ｈｉｖ 복제를 억제하는 피리미딘
TWI556820B (zh) Ｈｓｐ９０抑制劑之組合
ES2542326T3 (es) Inhibidores de la replicación del VIH
CA2837724C (en) Combination of mek inhibitors and selective inhibitors of aurora a kinase
AU2004213173B2 (en) HIV inhibiting 1,2,4-triazines
CN104507481B (zh) 用于治疗、改善或预防病毒疾病的7‑氧代‑4,7‑二氢‑吡唑并[1,5‑a]嘧啶衍生物
ES2361566T3 (es) Uso de inhibidores de parp-1.
JP2018087205A (ja) ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
ES2717898T3 (es) Efecto potenciador para agentes antitumorales
EP1682547B1 (en) Rsv polymerase inhibitors
JP2004535363A (ja) 血液腫瘍および血液癌を処置する方法
WO2017173973A1 (zh) 氮杂色胺酮衍生物作为ido1和/或tdo抑制剂的用途
AU2002307140B2 (en) Use of N-Phenyl-2-Pyrimidineamine Derivatives against mast cell-based diseases like allergic disorders
RU2450814C2 (ru) Производные пиримидиламинобензамида, предназначенные для лечения нейрофиброматоза
KR20090010112A (ko) Ｍｔｏｒ 억제제 및 ｒａｆ 키나제 억제제를 포함하는 약학적 조합물
CA2145545A1 (en) "sensitizing hiv-1 inhibitors" sensitize hiv infected individuals to "non-nucleoside hiv treatment drugs"
KR20080004563A (ko) 전신 비만세포증의 치료를 위한 피리미딜아미노벤즈아미드유도체의 용도
ES2215327T3 (es) Composicion de medicamento inmunomodulador.
JP2007523192A (ja) 広域スペクトラム抗癌剤としてのβ−ラパコンの使用
CN118019739A (zh) Eif4e抑制剂及其用途
CA1297021C (en) Therapeutic agent for the treatment of peptic ulcer disease
CN118103368A (zh) Eif4e抑制剂及其用途
TW201024294A (en) Combination of Hsp90 and herceptin inhibitors
JP2007523190A (ja) 肺癌の治療のためのβ−ラパコンの使用

Legal Events

Date Code Title Description
FZDE Discontinued